The Medlive Advisory Board is a collaboration of esteemed medical experts and key opinion leaders in oncology, neurology, and cardiology. The distinguished panel of renowned specialists will play a crucial role in enhancing the design and content for Medlive’s clinician and patient education programs. The Advisory Board will ensure that Medlive remains at the forefront of medical education, providing the most up-to-date and relevant information for healthcare providers and patients alike.
Advisory Board
Dr. Ghassan Abou-Alfa, MD, JD, MBA, PhD(hc)
Attending Physician,
Memorial Sloan Kettering Cancer Center (MSK)
Professor of Medicine,
Weill Medical School at Cornell University
Ghassan Abou-Alfa, MD, JD, MBA, PhD(hc) is an Attending Physician at Memorial Sloan Kettering Cancer Center (MSK) and Professor of Medicine at Weill Medical School at Cornell University. Professor Abou-Alfa specializes in in the treatment of gastrointestinal malignancies and in particular, hepatocellular carcinoma (HCC), intrahepatic and extrahepatic cholangiocarcinoma (IHC), gallbladder cancer (GB), and fibrolamellar carcinoma (FLC). Professor Abou-Alfa is a member of the International Affairs Committee of the American Society of Clinical Oncology (ASCO) and serves as member of its Steering Committee. Professor Abou-Alfa is also the President for the International Society of Gastrointestinal Oncology (ISGIO). Professor Abou-Alfa majored in biology, earned his medical degree, and now serves as a trustee on the Board of Trustees of his alma mater the American University in Beirut (AUB). Professor Abou-Alfa completed his postdoctoral training in internal medicine, medical oncology, and hematology at Yale University, and received his MBA from Columbia University.
Dr. Hans Lee, MD
Director of Myeloma Research
SCRI Oncology Partners
Hans Lee, MD is director of multiple myeloma research at Sarah Cannon Research Institute. Dr Lee’s clinical and research efforts are focused on advancing the care and treatment of patients with multiple myeloma (MM). His primary research goals are developing novel approaches to treat MM through early-phase investigator-initiated and industry-sponsored clinical trials, with a strong translational emphasis to interrogate myeloma pathobiology and mechanisms of drug response and resistance. Dr. Lee’s research has been funded by the American Society of Clinical Oncology, the American Association for Cancer Research, and the Leukemia & Lymphoma Society. His work has been published in several peer-reviewed journals, including the New England Journal of Medicine, Lancet Oncology, Blood, and Leukemia.
Dr. Aaron Lisberg, MD
Assistant Professor of Clinical Medicine
David Geffen School of Medicine
University of California, Los Angeles (UCLA)
Aaron Lisberg, MD is a thoracic medical oncologist at the University of California, Los Angeles. He specializes in novel drug development, antibody-drug conjugates (ADCs), immunotherapy, and metabolically targeted therapies in patients with advanced malignancies, focusing on lung cancer. He is board-certified in hematology and medical oncology, and has a wide range of ongoing research projects, including the evaluation of factors predictive of response or toxicity to ADCs and immune checkpoint inhibitors, evaluation of novel metabolic therapies, and assessment of effective treatments in patients with targetable tumor alterations. He is the clinical principle investigator and sub-investigator of several clinical trials evaluating novel therapeutics in various malignancies.
Dr. Erin Michos, MD, MHS
Director of Women’s Cardiovascular Health Research
Associate Director of Preventive Cardiology
Associate Professor of Medicine Division of Cardiology, Johns Hopkins School of Medicine
Erin D. Michos, MD is an associate professor of medicine within the Division of Cardiology at the Johns Hopkins School of Medicine in Baltimore, MD, with a joint appointment in the department of epidemiology at the Johns Hopkins Bloomberg School of Public Health. Dr. Michos is director of Women’s Cardiovascular Health Research and associate director of preventive cardiology within the Johns Hopkins Ciccarone Center for the Prevention of Cardiovascular Disease. Her research focuses on cardio-obstetrics and cardiovascular disease in women; advanced lipid disorders; risk prediction for cardiovascular disease including the use of coronary artery calcium scores, markers of inflammation, and other biomarkers; and obesity and cardiometabolic diseases.
Dr. Neal Shore, MD, FACS
Director, START Carolinas/Carolina Urologic Research Center
Head of GU Oncology START Cancer Research
AUC Urology Specialists
Neal Shore, MD, FACS is medical director for the Carolina Urologic Research Center in Myrtle Beach, SC. He has conducted more than 400 clinical trials, focusing mainly on genitourinary oncology, and has authored more than 350 peer-reviewed publications and numerous book chapters. Dr. Shore serves on the Society for Immunotherapy of Cancer (SITC) Guidelines Committee for Bladder Cancer, as well as the boards of the Bladder Cancer Advocacy Network, Maple Tree Cancer Alliance, Alessa Therapeutics, Photocure, and the Duke Global Health Institute. He is chair of both the Prostate Cancer Academy and the Bladder/Kidney Cancer Academy and is co-chair of the annual American Urological Association (AUA) International Prostate Forum.
Dr. Tiffany Traina, MD, FASCO
Vice Chair, Department of Medicine
Associate Attending Physician
Breast Medicine Service
Memorial Sloan Kettering Cancer Center
Associate Professor of Medicine
Weill Cornell Medicine
Tiffany Traina, MD, FASCO, is an Associate Attending Physician on the Breast Medicine Service at Memorial Sloan Kettering Cancer Center. She serves as a Vice Chair for the Department of Medicine and Section Head of the Triple Negative Breast Cancer Clinical Research Program. Dr. Traina is Co-Chair of the MSK Outpatient Operations Committee as well as an Associate Professor of Medicine at Weill Cornell Medicine in New York City. Her research program centers on the development of therapies for patients with breast cancer, with a particular focus on Triple Negative Breast Cancer and the role of the androgen receptor. Furthermore, Dr. Traina is a founding member of the Translational Breast Cancer Research Consortium Triple Negative Breast Cancer Working Group.
